Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130).
Rats transplanted with the ascites hepatoma Yoshida AH-130 developed a severely progressive cachexia, characterised by marked alterations in protein and lipid metabolism. In particular, high levels of serum triglycerides and free fatty acids were associated with altered levels and distribution of plasma cholesterol, with increased total and very low-density lipoprotein-low-density lipoprotein (VLDL-LDL) cholesterol and reduced high-density lipoprotein (HDL) cholesterol. The tumour cells showed high rates of cholesterol synthesis and elevated content of free and esterified cholesterol, whereas total cholesterol synthesis was reduced in the host liver. To determine whether these perturbations could be related to the elevation of tumour necrosis factor alpha (TNF-alpha) previously shown in the AH-130 bearers (Tessitore L, Costelli P, Baccino FM 1993, Br J Cancer, 67, 15-23), either anti-TNF polyclonal antibodies or non-immune IgGs were injected daily after tumour transplantation. The anti-TNF treatment neither affected tumour growth nor prevented the serum cholesterol changes, while attenuating the hypertriglyceridaemia and the elevated serum free fatty acid levels. These data indicate that TNF does not appear to be directly involved in the altered cholesterol metabolism in AH-130 hosts, thus supporting the view that cholesterol metabolism and lipid metabolism are regulated differently during tumour growth.
Dessì
S
S
Istituto di Patologia Sperimentale, Università di Cagliari, Italy.
Batetta
B
B
Spano
O
O
Bagby
G J
GJ
Tessitore
L
L
Costelli
P
P
Baccino
F M
FM
Pani
P
P
Argilès
J M
JM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001201:Ascites; D002100:Cachexia / Q000209:etiology / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D007116:Immunization, Passive; D008074:Lipoproteins / Q000097:blood; D008099:Liver / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D008297:Male; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D009368:Neoplasm Transplantation; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology
D000911:Antibodies, Monoclonal; D008076:Cholesterol, HDL; D008074:Lipoproteins; D009363:Neoplasm Proteins; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D002784:Cholesterol